Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).
Renée J.G. Arnold, PharmD, RPh
Advertisement
Articles by Renée J.G. Arnold, PharmD, RPh
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease
Published: February 21st 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
3
Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC
4
When to Call, When to Counsel: Statin Drug Interactions
5
